{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:40:21Z","timestamp":1789508421847,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2021,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myeloma cells produce excessive levels of dickkopf-1 (DKK1), which mediates the inhibition of Wnt signaling in osteoblasts, leading to multiple myeloma (MM) bone disease. Nevertheless, the precise mechanisms underlying DKK1 overexpression in myeloma remain incompletely understood. Herein, we provide evidence that hypoxia promotes<jats:italic>DKK1<\/jats:italic>expression in myeloma cells. Under hypoxic conditions, p38 kinase phosphorylated cAMP-responsive element-binding protein (CREB) and drove its nuclear import to activate<jats:italic>DKK1<\/jats:italic>transcription. In addition, high levels of DKK1 were associated with the presence of focal bone lesions in patients with t(4;14) MM, overexpressing the histone methyltransferase MMSET, which was identified as a downstream target gene of hypoxia-inducible factor (HIF)-1\u03b1. Furthermore, we found that CREB could recruit MMSET, leading to the stabilization of HIF-1\u03b1 protein and the increased dimethylation of histone H3 at lysine 36 on the DKK1 promoter. Knockdown of CREB in myeloma cells alleviated the suppression of osteoblastogenesis by myeloma-secreted DKK1 in vitro. Combined treatment with a CREB inhibitor and the hypoxia-activated prodrug TH-302 (evofosfamide) significantly reduced MM-induced bone destruction in vivo. Taken together, our findings reveal that hypoxia and a cytogenetic abnormality regulate DKK1 expression in myeloma cells, and provide an additional rationale for the development of therapeutic strategies that interrupt DKK1 to cure MM.<\/jats:p>","DOI":"10.1038\/s41388-020-01590-8","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T18:03:46Z","timestamp":1610129026000},"page":"1231-1241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9974-5621","authenticated-orcid":false,"given":"Yinyin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2416","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-6646","authenticated-orcid":false,"given":"Beizhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0677-8097","authenticated-orcid":false,"given":"Zhiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"1590_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"1590_CR2","volume":"3","author":"J Adamik","year":"2019","unstructured":"Adamik J, Roodman GD, Galson DL. Epigenetic-based mechanisms of osteoblast suppression in multiple myeloma bone disease. JBMR. 2019;3:e10183.","journal-title":"JBMR"},{"key":"1590_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2141.2004.05084.x","volume":"126","author":"F Silvestris","year":"2004","unstructured":"Silvestris F, Cafforio P, Calvani N, Dammacco F. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol. 2004;126:475\u201386.","journal-title":"Br J Haematol"},{"key":"1590_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0037-4","volume":"8","author":"E Terpos","year":"2018","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8:7.","journal-title":"Blood Cancer J"},{"key":"1590_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/978-3-319-40320-5_14","volume":"169","author":"H Eda","year":"2016","unstructured":"Eda H, Santo L, David Roodman G, Raje N. Bone disease in multiple myeloma. Cancer Treat Res. 2016;169:251\u201370.","journal-title":"Cancer Treat Res"},{"key":"1590_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","volume":"33","author":"H van Andel","year":"2019","unstructured":"van Andel H, Kocemba KA, Spaargaren M, Pals ST. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia. 2019;33:1063\u201375.","journal-title":"Leukemia"},{"key":"1590_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1182\/blood-2008-01-132134","volume":"112","author":"YW Qiang","year":"2008","unstructured":"Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood. 2008;112:196\u2013207.","journal-title":"Blood"},{"key":"1590_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.blre.2013.08.002","volume":"27","author":"F Zhou","year":"2013","unstructured":"Zhou F, Meng S, Song H, Claret FX. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention. Blood Rev. 2013;27:261\u20137.","journal-title":"Blood Rev"},{"key":"1590_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bone.2015.01.008","volume":"75","author":"G Intini","year":"2015","unstructured":"Intini G, Nyman JS. Dkk1 haploinsufficiency requires expression of Bmp2 for bone anabolic activity. Bone. 2015;75:151\u201360.","journal-title":"Bone"},{"key":"1590_CR10","first-page":"349","volume":"29","author":"M Abe","year":"2019","unstructured":"Abe M. [Wnt signaling in myeloma.]. Clin Calcium. 2019;29:349\u201355.","journal-title":"Clin Calcium"},{"key":"1590_CR11","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1182\/blood-2007-03-082529","volume":"110","author":"J Qian","year":"2007","unstructured":"Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007;110:1587\u201394.","journal-title":"Blood"},{"key":"1590_CR12","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1182\/blood-2006-11-056747","volume":"109","author":"S Colla","year":"2007","unstructured":"Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, et al. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood. 2007;109:4470\u20137.","journal-title":"Blood"},{"key":"1590_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","volume":"114","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114:371\u20139.","journal-title":"Blood"},{"key":"1590_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1359\/jbmr.081104","volume":"24","author":"DJ Heath","year":"2009","unstructured":"Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009;24:425\u201336.","journal-title":"J Bone Miner Res."},{"key":"1590_CR15","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","volume":"109","author":"S Yaccoby","year":"2007","unstructured":"Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109:2106\u201311.","journal-title":"Blood"},{"key":"1590_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.bone.2013.01.012","volume":"53","author":"S Pozzi","year":"2013","unstructured":"Pozzi S, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, et al. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone. 2013;53:487\u201396.","journal-title":"Bone"},{"key":"1590_CR17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0609.2007.00974.x","volume":"80","author":"P Tosi","year":"2008","unstructured":"Tosi P, Terragna C, Testoni N, Zamagni E, Renzulli M, Tacchetti P, et al. Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. Eur J Haematol. 2008;80:31\u20136.","journal-title":"Eur J Haematol"},{"key":"1590_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367.","journal-title":"Am J Hematol"},{"key":"1590_CR19","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.3324\/haematol.2018.194688","volume":"104","author":"B Muz","year":"2019","unstructured":"Muz B, Buggio M, Azab F, de la Puente P, Fiala M, Padval MV, et al. PYK2\/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma. Haematologica. 2019;104:e310\u20133.","journal-title":"Haematologica"},{"key":"1590_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41375-019-0588-4","volume":"34","author":"JJ Garces","year":"2020","unstructured":"Garces JJ, Simicek M, Vicari M, Brozova L, Burgos L, Bezdekova R, et al. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia. 2020;34:589\u2013603.","journal-title":"Leukemia"},{"key":"1590_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep26859","volume":"6","author":"H Zhu","year":"2016","unstructured":"Zhu H, Zhang Y, Shi Z, Lu D, Li T, Ding Y, et al. The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K\/AKT and MAPK Pathways. Sci Rep. 2016;6:26859.","journal-title":"Sci Rep"},{"key":"1590_CR22","doi-asserted-by":"publisher","first-page":"11719","DOI":"10.1074\/jbc.M010263200","volume":"276","author":"JC Craig","year":"2001","unstructured":"Craig JC, Schumacher MA, Mansoor SE, Farrens DL, Brennan RG, Goodman RH. Consensus and variant cAMP-regulated enhancers have distinct CREB-binding properties. J Biol Chem. 2001;276:11719\u201328.","journal-title":"J Biol Chem"},{"key":"1590_CR23","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00432-014-1642-2","volume":"140","author":"KT Guo","year":"2014","unstructured":"Guo KT, Fu P, Juerchott K, Motaln H, Selbig J, Lah T, et al. The expression of Wnt-inhibitor DKK1 (Dickkopf 1) is determined by intercellular crosstalk and hypoxia in human malignant gliomas. J cancer Res Clin Oncol. 2014;140:1261\u201370.","journal-title":"J cancer Res Clin Oncol"},{"key":"1590_CR24","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1080\/15384101.2017.1317408","volume":"16","author":"M Schoenhals","year":"2017","unstructured":"Schoenhals M, Jourdan M, Bruyer A, Kassambara A, Klein B, Moreaux J. Hypoxia favors the generation of human plasma cells. Cell Cycle. 2017;16:1104\u201317.","journal-title":"Cell Cycle"},{"key":"1590_CR25","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1002\/cam4.1596","volume":"7","author":"C Wu","year":"2018","unstructured":"Wu C, Yang T, Liu Y, Lu Y, Yang Y, Liu X, et al. ARNT\/HIF-1beta links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. Cancer Med. 2018;7:3899\u2013911.","journal-title":"Cancer Med"},{"key":"1590_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.trsl.2014.12.001","volume":"165","author":"E Borsi","year":"2015","unstructured":"Borsi E, Terragna C, Brioli A, Tacchetti P, Martello M, Cavo M. Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma. Transl Res: J Lab Clin Med. 2015;165:641\u201350.","journal-title":"Transl Res: J Lab Clin Med"},{"key":"1590_CR27","first-page":"706","volume":"4","author":"A Bhaskar","year":"2016","unstructured":"Bhaskar A, Tiwary BN. Hypoxia inducible factor-1 alpha and multiple myeloma. Int J Adv Res. 2016;4:706\u201315.","journal-title":"Int J Adv Res"},{"key":"1590_CR28","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/leu.2013.24","volume":"27","author":"P Storti","year":"2013","unstructured":"Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, et al. Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia. 2013;27:1697\u2013706.","journal-title":"Leukemia"},{"key":"1590_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085571","volume":"9","author":"Z Liu","year":"2014","unstructured":"Liu Z, Li T, Jiang K, Huang Q, Chen Y, Qian F. Induction of chemoresistance by all-trans retinoic acid via a noncanonical signaling in multiple myeloma cells. PLoS ONE. 2014;9:e85571.","journal-title":"PLoS ONE"},{"key":"1590_CR30","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1038\/sj.onc.1209439","volume":"25","author":"O Aguilera","year":"2006","unstructured":"Aguilera O, Fraga MF, Ballestar E, Paz MF, Herranz M, Espada J, et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene. 2006;25:4116\u201321.","journal-title":"Oncogene"},{"key":"1590_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040955","volume":"7","author":"H Wang","year":"2012","unstructured":"Wang H, Li Q, Chen H. Genistein affects histone modifications on Dickkopf-related protein 1 (DKK1) gene in SW480 human colon cancer cell line. PloS ONE. 2012;7:e40955.","journal-title":"PloS ONE"},{"key":"1590_CR32","first-page":"636514","volume":"2014","author":"Z Xie","year":"2014","unstructured":"Xie Z, Chng WJ. MMSET: role and therapeutic opportunities in multiple myeloma. BioMed Res Int. 2014;2014:636514.","journal-title":"BioMed Res Int"},{"key":"1590_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood-2010-07-298349","volume":"117","author":"E Martinez-Garcia","year":"2011","unstructured":"Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood. 2011;117:211\u201320.","journal-title":"Blood"},{"key":"1590_CR34","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1128\/MCB.00204-12","volume":"32","author":"P Yang","year":"2012","unstructured":"Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, et al. Histone methyltransferase NSD2\/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol. 2012;32:3121\u201331.","journal-title":"Mol Cell Biol"},{"key":"1590_CR35","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"1590_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679\u201386.","journal-title":"Blood"},{"key":"1590_CR37","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/s41388-019-1037-6","volume":"39","author":"Y Xie","year":"2020","unstructured":"Xie Y, Liu J, Jiang H, Wang J, Li X, Wang J, et al. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma. Oncogene. 2020;39:922\u201334.","journal-title":"Oncogene"},{"key":"1590_CR38","doi-asserted-by":"publisher","first-page":"6393","DOI":"10.1158\/0008-5472.CAN-12-2664","volume":"72","author":"J He","year":"2012","unstructured":"He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, et al. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res. 2012;72:6393\u2013402.","journal-title":"Cancer Res"},{"key":"1590_CR39","doi-asserted-by":"publisher","first-page":"353ra113","DOI":"10.1126\/scitranslmed.aad8949","volume":"8","author":"H Liu","year":"2016","unstructured":"Liu H, Liu Z, Du J, He J, Lin P, Amini B, et al. Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Sci Transl Med. 2016;8:353ra113.","journal-title":"Sci Transl Med"},{"key":"1590_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/0253-7176.116232","volume":"35","author":"J Charan","year":"2013","unstructured":"Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013;35:121\u20136.","journal-title":"Indian J Psychol Med"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-01590-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-01590-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-01590-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T07:05:33Z","timestamp":1697526333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01590-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,2,18]]}},"alternative-id":["1590"],"URL":"https:\/\/doi.org\/10.1038\/s41388-020-01590-8","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"4 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors concur with the submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was approved by the Ethic Committee of Tianjin Medical University, and Ethic Committee of Chongqing Medical University. All the protocols were conformed to the Ethical Guidelines of the World Medical Association Declaration of Helsinki. Signed informed consent was obtained from all participating individuals prior to participation in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}